Latest Stories
Uncategorized
Roche’s $1.05 Billion Bet on AI Pathology Nears the Finish Line
Roche's deal to acquire AI pathology startup PathAI, announced in May, is working toward a close as the pharmaceutical giant looks to speed up cancer diagnosis using artificial intelligence.
Uncategorized
Tempus AI’s $1.5 Billion Personalis Deal Tests Investor Patience on Genomics Bet
Tempus AI is pushing ahead with a roughly $1.5 billion all-stock acquisition of genomic testing company Personalis, a bet on expanding its precision oncology platform that sent both companies' shares lower when it was announced.
Uncategorized
Pfizer Licenses Chai Discovery’s AI Platform to Speed Up Its Own Drug Pipeline
Pfizer has licensed Chai Discovery's AI protein design platform for its drug pipeline, as the startup diversifies beyond its existing Eli Lilly partnership following a $400 million funding round.
Uncategorized
AI Drug Discovery Licensing Deals Hit $47.1 Billion in Just the First Half of 2026
AI drug discovery licensing deals hit $47.1 billion in the first half of 2026, already surpassing all of 2025, even as no AI-discovered drug has yet won full FDA approval.
In-Depth
Uncategorized
Takeda Signs $600 Million AI Drug Discovery Deal With Insilico Medicine
Takeda signed a $600 million AI drug discovery deal with Insilico Medicine, joining Eli Lilly and AstraZeneca in a wave of major pharma bets on AI-driven drug development in 2026.
Uncategorized
Eli Lilly Expands AI Drug Discovery Bet With $2.75 Billion Insilico Medicine Deal
Eli Lilly signed a deal worth up to $2.75 billion with Insilico Medicine to develop new drugs using AI, one of 2026's largest AI drug discovery partnerships.
Uncategorized
WellSpan Health Expands Hippocratic AI Deal to Platform-Wide Use Across Every Care Setting
WellSpan Health expanded its partnership with Hippocratic AI on July 30, 2026 into a platform-wide, multi-year deal covering inbound, outbound, ambulatory, and inpatient care, moving its Ana voice agent beyond scheduling into clinical navigation.
Uncategorized
AstraZeneca Signs Up to $1.5 Billion AI Drug-Discovery Deal With insitro to Target MASH and Cardiomyopathies
AstraZeneca signed an AI drug-discovery deal with insitro on October 15, 2026 worth up to $1.5 billion, targeting MASH and cardiomyopathies using insitro's Virtual Human machine-learning platform.
Uncategorized
Chai Discovery Raises $400 Million at $3.8 Billion Valuation as AI Drug Design Reaches Eli Lilly and Pfizer
Chai Discovery has raised a $400 million Series C round led by Index Ventures at a $3.8 billion valuation, nearly tripling its worth from seven months earlier as its AI-designed antibodies move into partnerships with Eli Lilly and Pfizer.
